Avanafil: Completed Phase III enrollment

Vivus completed enrollment of about 650 patients in the double-blind, U.S. Phase III REVIVE trial (TA-301) comparing 50, 100 and 200 mg of oral avanafil vs. placebo. Last year, Deerfield Management Co...